| 钟莹,戴红,陈金锦.双歧杆菌三联活菌散联合度洛西汀治疗肠易激综合征(IBSD)的临床疗效及对血清5-HT、脑肠肽水平的影响[J].浙江中西医结合杂志,2018,28(4): |
| 双歧杆菌三联活菌散联合度洛西汀治疗肠易激综合征(IBSD)的临床疗效及对血清5-HT、脑肠肽水平的影响 |
| Clinical efficacy of Bifidobacterium triple viable powder combined with Duloxetine in the treatment of irritable bowel syndrome (IBSD) and its effect on serum levels of 5-HT and brain gut peptide |
| 投稿时间：2017-04-04 修订日期：2018-01-12 |
| DOI： |
| 中文关键词: 【关键词】 肠易激综合征 双歧杆菌三联活菌散 度洛西汀 临床疗效 脑肠肽 |
| 英文关键词:Irritable bowel syndrome Bifidobacterium triple viable powder Duloxetine Clinical efficacy Brain gut peptide |
| 基金项目: |
|
| 摘要点击次数: 684 |
| 全文下载次数: 2 |
| 中文摘要: |
| 【】目的 探讨双歧杆菌三联活菌散联合度洛西汀治疗肠易激综合征(IBSD)的临床疗效及对血清5-羟色胺(5-HT)、脑肠肽水平的影响。方法 选取我院消化内科收治的IBSD患者172例,按随机数字表法分组,对照组86例予以双歧杆菌三联活菌散治疗,研究组86例在对照组基础上予以度洛西汀治疗,测定两组间血清5-HT、血管活性肠肽(VIP)、P物质(SP)、降钙素基因相关肽(CGRP)水平、血清炎症因子水平、精神状态评分,同时比较临床疗效及不良反应发生率。结果 对照组总有效率(81.39%)低于研究组总有效率(91.86%),具有统计学意义(P＜0.05)；与对照组比较,研究组治疗后血清5-HT、VIP、SP、CGRP水平较低,治疗后血清IL-6、IL-8、IL-1β水平较低,治疗后SAS、SDS评分较低,具有统计学意义(P＜0.05)；治疗中出现的不良反应主要有恶心呕吐、消化不良、眩晕、嗜睡等,两组间不良反应发生率无明显差异(P＞0.05)。结论 双歧杆菌三联活菌散联合度洛西汀治疗IBSD的临床疗效确切,能够明显降低血清5-HT及VIP、SP、CGRP等脑肠肽水平,降低相关炎症因子水平,改善患者的精神状态,且具有较高的安全性。 |
| 英文摘要: |
| Objective To investigate the clinical efficacy of Bifidobacterium triple viable powder combined with Duloxetine in the treatment of irritable bowel syndrome (IBSD) and its effect on serum levels of 5- hydroxytryptamine(5-HT)and brain gut peptide. Methods 172 patients with IBSD from the Department of Gastroenterology in our hospital were selected and divided into 2 groups, 86 cases in the control group treated with Bifidobacterium triple viable powder, 86 cases in the experiment group received Duloxetine on the basis of the control group, serum levels of 5-HT, vasoactive intestinal peptide (VIP), substance P (SP) and calcitonin gene related peptide (CGRP), serum levels of inflammatory factors, mental status score, and the clinical effect and adverse reaction rate were compared after the treatment. Results The total effective rate in the control group(81.39%)was lower than the experiment group(91.86%), with significant difference (P<0.05); compared with the control group, serum 5-HT、VIP、SP、CGRP levels were lower, after treatment in the experiment group, serum IL-6、IL-8、IL-1β levels were lower, SAS、SDS score were lower after treatment, with significant difference (P<0.05). Conclusion The clinical curative effect of Bifidobacterium triple viable powder combined with Duloxetine in the treatment of IBSD is exactly, can significantly reduce serum levels 5-HT and VIP, SP, CGRP and other brain gut peptide, reduce the level of inflammatory cytokines, improve the patient"s mental state, and has high security. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
